Account Info
Log Out
English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
Jaguar8 commented on a stock · May 7 15:23

$Aquestive Therapeutics (AQST.US)$ NEWS Aquestive Therapeuti...

NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negative
Net loss of $12.8 million in Q1 2024 compared to net income in Q1 2023
Non-GAAP adjusted EBITDA loss of $7.2 million in Q1 2024
Research and development expenses increased to $5.9 million in Q1 2024
Selling, general, and administrative expenses increased to $10.7 million in Q1 2024
Full-year 2024 financial guidance projects a non-GAAP adjusted EBITDA loss of $22 to $26 million
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
3
Translate
Report
6210 Views
Comment
Sign in to post a comment
avatar
Jaguar8
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7396Visitors
Follow